Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Rating of “Moderate Buy” by Brokerages

Voyager Therapeutics, Inc. (NASDAQ:VYGR) has received an average recommendation of “Moderate Buy” from the six research firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $12.1460.

A number of analysts have recently weighed in on the company. Wedbush reissued an “outperform” rating and issued a $8.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, November 11th. Weiss Ratings reiterated a “sell (d)” rating on shares of Voyager Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Finally, HC Wainwright cut their price objective on shares of Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, November 12th.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, CFO Nathan D. Jorgensen sold 7,666 shares of the company’s stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $4.78, for a total transaction of $36,643.48. Following the transaction, the chief financial officer owned 123,834 shares in the company, valued at approximately $591,926.52. This represents a 5.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 6.39% of the company’s stock.

Institutional Investors Weigh In On Voyager Therapeutics

Large investors have recently made changes to their positions in the stock. Privium Fund Management B.V. raised its stake in Voyager Therapeutics by 16.6% in the 2nd quarter. Privium Fund Management B.V. now owns 25,241 shares of the company’s stock worth $79,000 after acquiring an additional 3,596 shares during the last quarter. American Century Companies Inc. raised its stake in shares of Voyager Therapeutics by 5.1% in the second quarter. American Century Companies Inc. now owns 138,269 shares of the company’s stock worth $430,000 after purchasing an additional 6,748 shares during the last quarter. Jain Global LLC lifted its holdings in shares of Voyager Therapeutics by 44.1% during the third quarter. Jain Global LLC now owns 28,104 shares of the company’s stock worth $131,000 after purchasing an additional 8,600 shares during the period. AXQ Capital LP boosted its position in Voyager Therapeutics by 47.8% in the third quarter. AXQ Capital LP now owns 27,360 shares of the company’s stock valued at $128,000 after buying an additional 8,844 shares during the last quarter. Finally, Wexford Capital LP purchased a new stake in Voyager Therapeutics in the third quarter valued at approximately $42,000. 48.03% of the stock is owned by hedge funds and other institutional investors.

Voyager Therapeutics Stock Down 1.6%

Shares of Voyager Therapeutics stock opened at $4.28 on Tuesday. The company has a market cap of $237.97 million, a P/E ratio of -1.98 and a beta of 1.23. The firm’s 50 day moving average price is $4.50 and its 200-day moving average price is $3.81. Voyager Therapeutics has a 52-week low of $2.64 and a 52-week high of $6.69.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Monday, November 10th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.06. Voyager Therapeutics had a negative net margin of 404.85% and a negative return on equity of 48.94%. The company had revenue of $11.15 million during the quarter, compared to the consensus estimate of $7.86 million. As a group, equities research analysts forecast that Voyager Therapeutics will post -0.91 EPS for the current fiscal year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.